目的 探讨标准桃金娘油肠溶胶囊联合二羟丙茶碱治疗慢性喘息性支气管炎的临床疗效。方法 选取2022年1月—2024年1月山东省立第三医院收治的慢性喘息性支气管炎110例，随机分为对照组（55例）和治疗组（55例）。对照组口服二羟丙茶碱片，0.2 g/次，3次/d；治疗组在对照组的基础上口服标准桃金娘油肠溶胶囊，1粒/次，2次/d。两组患者连续服用药物15 d。观察两组患者临床疗效，比较治疗前后两组患者临床症状好转时间，气道重塑因子碱性成纤维细胞生长因子（b-FGF）、血小板衍生生长因子（PDGF-BB）和血管内皮生长因子（VEGF）水平，及炎性因子白细胞介素-13（IL-13）、肿瘤坏死因子-α（TNF-α）、白细胞介素-10（IL-10）和C反应蛋白（CRP）水平。结果 治疗后，治疗组总有效率为94.55%，明显高于对照组（81.82%，P＜0.05）。治疗后，与对照组比较，治疗组体征好转时间均明显缩短（P＜0.05）。治疗后，两组患者b-FGF、PDGF-BB、VEGF指标水平比治疗前明显降低（P＜0.05），且治疗后治疗组的指标水平均显著低于对照组（P＜0.05）。治疗后，两组患者IL-13、TNF-α、CRP水平比治疗前明显降低，而IL-10明显升高（P＜0.05），且治疗后治疗组IL-13、TNF-α、CRP和IL-10水平改善更明显（P＜0.05）。结论 标准桃金娘油肠溶胶囊与二羟丙茶碱协同治疗，能较好地纠正慢性喘息性支气管炎症状，进而改善支气管气道结构的重塑，减轻气道炎症反应。

Objective To explore the therapeutic effect and Myrtol Standardized Enteric Coated Soft Capsules combined with diprophylline in treatment of chronic asthmatic bronchitis. Methods Patients (110 cases) with chronic asthmatic bronchitis in Shandong Provincial Third Hospital from January 2022 to January 2024 were randomly divided into control (55 cases) and treatment (55 cases) group. Patients in the control group were po administered with Diprophylline Tablets, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Myrtol Standardized Enteric Coated Soft Capsules, 1 grain/time, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the clinical symptom improvement time, the levels of airway remodeling factor indicators b-FGF, PDGF-BB and VEGF, and the levels of inflammatory factor IL-13, TNF-α, CRP and IL-10 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 94.55%, which was significantly higher than that in the control group (81.82%, P < 0.05). After treatment, compared with the control group, the time for improving physical signs in the treatment group was significantly shortened (P < 0.05). After treatment, the levels of b-FGF, PDGF-BB, and VEGF in two groups were significantly lower than those before treatment (P < 0.05), and the levels of indicators in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of IL-13, TNF-α, and CRP in two groups were significantly lower than before treatment, while IL-10 was significantly increased (P < 0.05). After treatment, the levels of IL-13, TNF-α, CRP and IL-10 were improved more significantly in the treatment group (P < 0.05). Conclusion The synergistic treatment of Myrtol Standardized Enteric Coated Soft Capsules and Diprophylline Tablets can better correct the symptoms of chronic wheezing bronchitis, thereby improving the remodeling of bronchial and airway structure and reducing airway inflammatory reactions.

R974